Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

Abstract

IL-2 can produce a modest response rate in patients with metastatic melanoma including patients with durable complete responses. S.c. or cutaneous disease only and vaccination with gp100:209-217(210M) peptide was associated with significant increase in response rates.